Updated Tonix stock price forecast models factor in peer performance in micro-cap biotech, projecting relative strength if sector capital inflows continue. Market observers started the day gloomy. On Wednesday morning, JPMorgan Chase CEO Jamie Dimon said he believed the financial market turmoil would tip the U.S. economy into recession. “I think probably that’s a likely outcome, because markets, I mean, when you see a 2000-point decline [in the Dow Jones Industrial Average], it sort of feeds on itself, doesn’t it,” Dimon said on Fox Business’ “Mornings With Maria” show. As of January 30, 2025, Tonix Pharmaceuticals stock is trading around $0.40, exhibiting a 160% increase over the past three months. While Tonix’s recent market capitalization stands around $75 million, the stock’s 52-week range provides a picture of its volatility , fluctuating between a low of $0.12 and a high of $12.48. The current share price, considerably below its 52-week high, may present a value opportunity for investors who believe in the company’s long-term prospects. These fluctuations reflect the inherent volatility often seen in the biotech sector , especially for clinical-stage companies like Tonix. Tonix stock price forecast indicates macroeconomic factors such as interest rate policy could influence investor appetite for early-stage biotech investments.